Compare Mesoblast Limited (MESO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Direxion Daily TSLA Bull 2X Shares trades at $10.88. The key difference: Mesoblast Limited is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| MESO | TSLL | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $23.03 |
52-Week Low | $12.88 | $10.29 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TSLL is trading at $10.72, down 5.84% with a bearish technical outlook. The stock faces selling pressure with moving averages indicating a downtrend and key resistance at $12. Recent news highlights upcoming Tesla earnings as a potential catalyst, though financial ratios remain unavailable for fundamental assessment.
The stock's outlook is cautious due to technical weakness and lack of current financial data. Investment opportunity hinges on Tesla's upcoming earnings report, while risks include sustained bearish momentum and dependency on Tesla's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
